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Abstract. Bisphosphonates exert a potent inhibitory
eﬀect on bone resorption. Several studies have been
performed, with contradictory results, to ascertain
whether the eﬀect of bisphosphonates on osteoclasts
could be produced, at least in part, by modulation of the
synthesis of resorption-promoting factors by osteo-
blasts. The aim of this study was to evaluate the eﬀect of
etidronate (10)4–10)9 M) and alendronate (10)7–10)12
M) on the production of IL-6 and IL-11 using human
osteoblast cultures. Cytokines were quantiﬁed by ELI-
SA, and mRNA expression was tested. Treatment with
alendronate and etidronate had no eﬀect on the syn-
thesis of IL-6 or IL-11, and IL-6 and IL-11 mRNA
levels. These results were obtained both in nonstimu-
lated cultures and in cultures stimulated by means of
TNF-a, IL-1b, and TNF-a+IL-1b, with or without
FCS. In conclusion, a possible indirect osteoclast-med-
iated eﬀect of alendronate and etidronate on bone re-
sorption would not be exerted through reduction in
osteoblastic synthesis of IL-6 and IL-11.
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Bisphosphonates are potent inhibitors of bone resorp-
tion when tested in diﬀerent systems, both in vivo and
in vitro. At present, there are two models that would
explain how this inhibition is produced. On the one
hand, owing to the high aﬃnity of bisphosphonates
for hydroxyapatite, the inhibiting eﬀect of these bone
matrix-linked compounds would result from their direct
action on the resorptive ability of osteoclasts [1–3].
Thanks to their endocytotic capacity osteoclasts would
internalize bisphosphonates, which in turn would inhibit
the metabolic reactions involved in osteoclast func-
tion. Bisphosphonates that closely resemble pyrophos-
phate (such as clodronate and etidronate) can be
metabolically incorporated into nonhydrolyzable
analogs of ATP. It is likely that intracellular accumu-
lation of these metabolites inhibits osteoclast function.
The more potent, nitrogen-containing bisphospho-
nates (such as pamidronate and ibandronate) are
not metabolized but can inhibit enzymes of the meval-
onate pathway, thereby preventing the biosynthesis
of isopropenoid compounds that are essential for
posttranslational modiﬁcation of small GTPases. These
GTPases are important signaling proteins regulating a
variety of cell processes required to maintain osteo-
clast activity and survival [4]. Loss of osteoclast func-
tion and apoptosis is probably the consequence of
function loss of one or more of these signaling proteins
[5–8].
On the other hand, several in vitro studies [9, 10]
failed to show the diﬀerences in inhibitory power on
bone resorption found in vivo among the diﬀerent
types of bisphosphonates. These diﬀerences appeared
when osteoclasts were co-cultured with osteoblasts
[11]. This ﬁnding suggests that the eﬀect of bis-
phosphonates on osteoclasts could be produced, at
least in part, by modulation of the synthesis of resorp-
tion-promoting [12] or resorption-inhibiting factors by
osteoblasts [13].
Among these resorption-promoting factors, IL-6 has
been postulated to be an autocrine/paracrine regulator
of bone resorption, and plays a role in the early stages of
osteoclastogenesis by promoting the formation of os-
teoclast precursors [14]. It has also been shown that cells
in giant cell tumor of bone (human osteoclastoma) have
receptors for this cytokine, which would stimulate the
resorptive activity of these cells. These latter ﬁndings
appear to suggest that IL-6 could inﬂuence not only the
early stages of osteoclast development, but also the ac-
tivity of mature osteoclasts [15]. IL-6 is produced, in
nanomolar quantities, by diﬀerent types of cells, in-
cluding monocyte-macrophages, ﬁbroblasts, and osteo-
blastic cells [16, 17]. Diﬀerent factors regulate the
production of IL-6 and include parathyroid hormone
(PTH), PTH-related protein (PTH-rP), 1,25-di-
hydroxyvitamin D3 (1,25(OH)2D3), estrogens, trans-
forming growth factor (TGF), interleukin-1 (IL-1), and
tumor-necrosis factor (TNF) [18]. Also, a recent study in
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cultures of rat osteoblastic cells showed that IL-6 in-
duces its own synthesis in osteoblasts using tran-
scriptional mechanisms [19]. In a preliminary study,
Passeri et al. [12] assessed IL-6 production by human
osteosarcoma cell-line MG-63, in response to diﬀer-
ent doses of alendronate and etidronate, and observed
a dose-dependent inhibition of IL-6 production by
these cells. These data appeared to suggest that IL-6
might be one of the resorption-promoting factors by
which bisphosphonates could inhibit the action of
osteoclasts.
IL-11 is another cytokine with pleiotropic action
whose spectrum of biological activity overlaps that of
IL-6. Like IL-6, it stimulates acute-phase protein syn-
thesis [20], B-cell immunoglobulin production [21], and
hemopoiesis [22]. IL-11 induces osteoclastogenesis and
is associated with osteolysis [23] by mediating the oste-
oclastogenic eﬀects of PTH, IL-1b, and TNF-a [24].
Osteoblasts and osteosarcoma cells (SaOS-2) have been
shown to be potent producers of IL-11 [25]. Even
though the action of IL-11 on osteoclasts is similar to
the action of IL-6, we are not aware of any report an-
alyzing the eﬀect of bisphosphonates on the production
of this cytokine by osteoblasts.
The purpose of the present study was to evaluate the
production of IL-6 and IL-11 by normal human osteo-
blasts in vitro, in response to diﬀerent doses of alendr-
onate and etidronate.
Materials and Methods
Reagents
Dulbecco’s phosphate-buﬀered saline (PBS) and Dulbecco’s
modiﬁed Eagle’s medium (DMEM) were purchased from
Gibco (Grand Island, NY). Fetal calf serum (FCS) and trypsin
were obtained from Biological Industries (Kibbutz Beth
Haemek, Israel). Cedaceria Industrial (Barcelona, Spain)
provided nylon mesh, and culture plasticware was purchased
from Corning (Corning, NY). 1,25(OH)2D3 was provided by
Roche (Basel, Switzerland). Recombinant human IL-1b and
TNF-a were obtained from R&D Systems, Inc. (Minneapolis,
MN). Alendronate (AHuBP) was generously provided by Dr.
Corral at Merck, Sharp & Dohme (West Point, PA); and
etidronate (HEBP) was acquired from Laboratorios Rubio
(Barcelona, Spain). The IL-6 ELISA kit was purchased from
Endogen, Inc. (Cambridge, MA) and the IL-11 kit from R&D
Systems, Inc. (Minneapolis, MN). Nylon membranes were
from Bio-Rad Laboratories (San Jose, CA).
Normal Human Osteoblast Culture
Cells were cultured as previously described [2, 6]. Brieﬂy, hu-
man bone cells were obtained from the surgical specimens of
three patients, two women aged 69 and 74 and one man aged
68, all undergoing surgery for degenerative joint disease. Os-
teoblasts were obtained from 1 to 2 mm explants of trabecular
bone placed on an 80 lm mesh maintained between two glass
rings and cultured in supplemented medium with 20% fetal calf
serum. Approximately 1 week later, osteoblasts started to grow
out from the explants over the mesh. Meshes were completely
covered by osteoblasts after 3–4 weeks. Cells were isolated
using 0.25% trypsin and then subcultured. Osteoblasts were
characterized by alkaline phosphatase activity (ALP) and
osteocalcin synthesis in response to stimulation with
1,25(OH)2D3. In all cases, cells were stained intensely by a
histochemical reaction for ALP and were found to secrete
osteocalcin after stimulation with 1,25(OH)2D3. All prolifera-
tion and diﬀerentiation assays were performed with cells from
the third to the ﬁfth passage.
Bisphosphonate Treatment
Alendronate (AHuBP) and etidronate (HEBP) were dissolved
in NaCl 0.9% at pH 7.4 to prepare the stock solutions at a
concentration of 10)3 M and 10)2 M, respectively. From these
stock solutions, the remaining concentrations were prepared
by serial dilutions in DMEM, with or without fetal calf serum
(FCS), and added to the osteoblast cultures in concentrations
ranging from 10)7 to 10)12 M for AHuBP and 10)4 to 10)9 M
for HEBP. These concentrations were detected taking into
account that the 50 eﬀective dose (ED50) of alendronate as a
bone resorption inhibitor is 2 · 10)9 mol/L and that ED50 of
etidronate as a bone inhibitor is 1 · 10)6 mol/L [11]. The
maximum concentration of both bisphosphonates used in the
study were chosen since higher concentrations aﬀect osteoblast
viability [31]. Each experiment was performed in triplicate.
IL-6 and IL-11 Assays
Cells from the third to the ﬁfth passage were plated in 24-
well plates at a density of 3 · 104 cells/well and incubated in
DMEM supplemented with FCS. After 24 hours, the medium
was changed and the cells were incubated for a further 48
hours with serum-free medium supplemented with 0.1% bovine
serum albumin (BSA). The AHuBP, HEBP, or vehicle was
then added and the cells were incubated for an additional 24
hours, with or without FCS. Human recombinant IL-1b (0.2
nm) or recombinant murine TNF-a (0.3 nm), or the combi-
Fig. 1. Eﬀect of TNF-a (0.3 nm) and IL-1b (0.2 nm) on IL-6
induction in human osteoblasts. Cultures were treated for 24 h
in the presence or absence of TNF-a, IL-1b, or TNF-a + IL-
1b, with or without FCS. The conditioned media were assessed
for IL-6 production by human IL-6-speciﬁc ELISA. IL-6
synthesis in cultures treated with TNF-a, IL-1b, or TNF-a +
IL-1b showed a statistically signiﬁcant increase compared with
those not stimulated (*P £ 0.0005). There are also diﬀerences
when cultures stimulated with IL-1b or TNF-a + IL-1b are
compared with TNF-a cultures (*P £ 0.0005), with or with-
out FCS. Data are expressed as mean ± SEM (n = 3)
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nation of IL-1b + TNF-a, were also added. At this stage, the
supernatants were collected and frozen at )80C. IL-6 and IL-
11 were measured in the conditioned medium by an enzyme-
linked immunoabsorbent assay (ELISA). The IL-6 kit detec-
tion limit was 1 pg/ml, and that of IL-11 was 8 pg/ml, IL-6 and
IL-11 were determined in medium with or without FCS to rule
out their presence in the medium or serum which might alter
the results of the study.
RNA Isolation and Northern Blot Analysis
Total cellular RNA was puriﬁed using the single-step acidi-
ﬁed guanidinium thyocianate phenol-chloroform extraction
method [27]. Equal amounts of RNA were size-fractioned by
electrophoresis on 1% agarose formaldehyde gels and trans-
ferred by passive blotting to nylon membranes. To conﬁrm
equal loading and the integrity of RNA samples, the gels
were stained with ethidium bromide and ribosomal RNAs
(28s and 18s) visualized by UV transillumination. The RNA
blots were prehybridized, hybridized with 32P-labeled cDNA
probes, washed under conditions of high stringency, then
studied by autoradiography. Clone pHuIL-11/PMT, a 1,250
base pair IL-11 cDNA in the EcoRI site of the PMX vector,
was kindly provided by Dr. Paul Schendel (Genetics Institute,
MA). The IL-6 human probe cloned was purchased from the
American Type Collection (Rockville, MD, USA), and hu-
man cyclophilin A probe was provided by Dr. FX Real
(IMIM, Barcelona, Spain). Densitometry was performed us-
ing a Gel Doc 2000 BioRad (Bio-Rad Laboratories, Hercules,
CA) scanning densitometer, and densitometry curve integra-
tion and analysis was accomplished using the Molecular
Analysis software package (Bio-Rad Laboratories, Hercules,
CA).
Statistical Analysis
Data are expressed as mean ± SEM. Hierarchically adjusted
analysis of variance (ANOVA) was used to compare the means
of diﬀerent quantitative variables among groups with inde-
Fig. 2. Eﬀect of diﬀerent doses of alendronate and etidronate
on TNF-a, IL-1b, or TNF-a + IL-1b-induced IL-6 secretion
in human osteoblasts. Cultures were treated for 24 h with
alendronate or etidronate in the presence or absence of TNF-
a, IL-1b, or TNF-a + IL-1b, with or without FCS. (A) Cul-
tures treated with alendronate without FCS, (B) alendronate
with FCS, (C) etidronate without FCS, (D) etidronate with
FCS. The conditioned media were assessed for IL-6 produc-
tion by a human IL-6-speciﬁc ELISA. No eﬀect of any of the
alendronate or etidronate concentrations tested was observed
on IL-6 synthesis in the cultures, with or without TNF-a, IL-
1b, or TNF-a + IL-1b, stimulation, with or without FCS.
Data are expressed as mean ± SEM (n = 3).
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pendent data. When ANOVA detected statistically signiﬁcant
diﬀerences, concentrations tested in each experiment were
compared using the Scheﬀe method. A P £ 0.05 was con-
sidered statistically signiﬁcant. Analysis was performed using
the SPSS statistical package (6.1.3, Copyright (c) SPSS Inc.,
1989–1995).
Results
Eﬀects of Alendronate and Etidronate on Stimulated IL-6
Production in Normal Human Osteoblasts
The results of our study show that normal human os-
teoblasts constitutively produce IL-6 (Fig. 2). The de-
tected concentration in culture supernatants was
2.490 ± 106 pg/30,000 cells. A statistically signiﬁcant
increase was observed (P = 0.0005) in IL-6 concentra-
tion when cultures were treated with TNF-a, IL-1b, or
TNF-a + IL-1b. These increases were higher when the
culture medium was supplemented with FCS. In addi-
tion, signiﬁcant diﬀerences (P = 0.0005) were also de-
tected in the degree of stimulation achieved with TNF-a,
IL-b, or TNF-a + IL-1b. The highest degree of stimu-
lation in IL-6 production was achieved with the com-
bination TNF-a + IL 1b, followed by IL-1b, and by
TNF-a (Fig. 1).
In our study, no signiﬁcant changes in IL-6 concen-
tration were detected in supernatants of cultures treated
with diﬀerent alendronate or etidronate concentrations.
These results were obtained in both nonstimulated cul-
tures and in cultures stimulated by means of TNFa, IL-
1b, and TNFa + IL-1b, with or without FCS (Fig. 2).
IL-6 was not detected when the culture medium was
analyzed with and without FCS.
Eﬀects of Alendronate and Etidronate on Stimulated IL-11
Production in Normal Human Osteoblasts
On analyzing IL-11 concentration in the supernatant of
nonstimulated human normal osteoblast cultures,
constitutive production of this cytokine was not found
(Fig. 4). IL-11values, when the cultures were stimulated
with TNF-a without the addition of FCS, were below
the detection limit of our technique (8 pg/ml). When
FCS was added to cultures treated with TNF-a, de-
tectable levels of IL-11 were found in the supernatants.
Stimulation with IL-1b or with a combination of TNF-
a + IL-1b was also associated with detectable IL-11
levels, regardless of whether FCS was added to the
medium. Statistically signiﬁcant diﬀerences (P =
0.0005) were found between stimulation achieved with
IL-1b and TNFa + IL-1b. The highest level of stimu-
lation of IL-11 production was obtained with the
combination TNFa + IL1b, with the addition of FCS
(Fig. 3).
In the present study, no signiﬁcant changes were
found in supernatant concentration of IL-11 among
cultures treated with six diﬀerent alendronate (10)7 and
10)12 M) or etidronate (10)4 and 10)9 M) concentra-
tions. These results were obtained both in nonstimulated
cultures and in those stimulated with TNFa, IL-1b, and
TNFa + IL-1b, either with or without FCS (Fig. 4). IL-
11 was not detected when the culture medium was an-
alyzed with and without FCS.
Eﬀects of Alendronate and Etidronate on mRNA IL-6 and
mRNA IL-11 Levels
In lysates of osteoblast cultures, constitutive presence of
IL-6-codifying but not of IL-11-codifying mRNA was
detected with Northern blot. Weak IL-11 expression
could be detected when FCS was added to the cultures.
After stimulation of cultures with TNF-a, IL-1b, or
TNF-a + IL1b, both IL-6 and IL-11-codifying mRNA
levels increased. The highest levels were obtained with
the combination TNF-a + IL1b and FCS. Their sizes
(2.5 and 1.5 kilobases) (Fig. 5A and 5B) are in accord
with the IL-11 mRNA transcripts described by Elias
et al. [25] in human lung ﬁbroblasts and epithelial-like
cells.
In cultures treated with three diﬀerent alendro-
nate (10)7, 10)9, 10)12 M) and etidronate (10)4, 10)6,
10)9 M) concentrations and stimulated with TNF-a +
IL1b and FCS, no diﬀerences were detected in levels
Fig. 3. Eﬀect of TNF-a (0.3 nm) and IL-1b (0.2 nm) on IL-11
induction in human osteoblasts. Cultures were treated for 24 h
in the presence or absence of TNF-a, IL-1b, or TNF-a + IL-
1b, with or without FCS. The conditioned media were assessed
for IL-11 production by a human IL-11-speciﬁc ELISA. IL-11
synthesis in cultures treated with IL-1b or TNF-a + IL-1b
showed a statistically signiﬁcant increase compared with those
treated with TNF-a alone, with and without FCS. In the ab-
sence of FCS, levels of IL-11 in cultures treated with TNF-a
were not detectable. Data are expressed as mean ± SEM
(n = 3, *P £ 0.0005)
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of IL-6-codifying or IL-11-codifying mRNA (Fig. 5A
and 5B).
Discussion
Our results show that non-neoplastic human osteoblasts
secrete IL-6 constitutively in vitro. Other authors previ-
ously detected constitutive synthesis of IL-6 in a cell line
obtained from human (MG63) or murine (UMR-106)
osteosarcoma [28, 29] and in non-neoplastic human os-
teoblasts [30]. Our study conﬁrms that stimulation of
non-neoplastic human osteoblasts with IL-1b and TNF-
a intensely increases IL-6 synthesis [30]. Of both stim-
ulating factors, IL-1b is the most powerful. The com-
bined addition of IL-1b and TNF-a resulted in the
highest increase in IL-6 secretion. As expected, the in-
crease in cytokine production was greater when FCS
was added to the culture medium than when it was not.
The present study provides the ﬁrst demonstration that
human osteoblasts do not have constitutive secretion of
IL-11 in vitro. Should this secretion actually take place,
it should be well below the sensitivity level of our ELISA
assay, i.e., 8 pg/ml. In this regard, we did not detect
constitutive expression of IL-11 mRNA by Northern
blot. In addition, our results show for the ﬁrst time that
IL-1b is a much stronger stimulator of osteoblastic IL-
11 secretion than TNF-a, since the latter is only eﬀective
when FCS is added to the culture medium. The addition
of both IL-1b and TNF-a resulted in the maximum in-
crease in secreted IL-11 levels. Accordingly, our ﬁndings
are consistent with the hypothesis that, in physiological
conditions, the modulating role of IL-6 and IL-11 in
Fig. 4. Eﬀect of diﬀerent doses of alendronate and etidronate
on TNF-a, IL-1b, or TNF-a + IL-1b-induced IL-11 secretion
in human osteoblasts. Cultures were treated for 24 h with
alendronate or etidronate in the presence or absence of TNF-
a, IL-1b, or TNF-a + IL-1b, with or without FCS. (A) Cul-
tures treated with alendronate without FCS, (B) alendronate
with FCS, (C) etidronate without FCS, (D) etidronate with
FCS. The conditioned media were assessed for IL-11 produc-
tion by a human IL-11-speciﬁc ELISA. No eﬀect of any of the
alendronate or etidronate concentrations tested was observed
on IL-11 synthesis in the cultures, with or without TNF-a, IL-
1b, or TNF-a + IL-1b stimulation, with or without FCS.
Data are expressed as mean ± SEM (n=3)
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bone resorption may be mediated, at least in part, by IL-
1b and TNF-a [18].
In the present study, we did not observe that
alendronate and etidronate had any eﬀect on osteo-
blastic IL-6 and IL-11 secretion or on the expression of
their respective mRNAs. This lack of eﬀect was con-
ﬁrmed for all tested concentrations of alendronate and
etidronate stimulated with IL-1b, TNF-a, or the com-
bination of both. This was also the case when cultures
were not stimulated, permitting us to rule out the pos-
sibility that these results were due to excessive cell
stimulation. On the other hand, in a previous study, we
showed that concentrations of alendronate and etidro-
nate used in the present experiment did not aﬀect via-
bility, proliferation, or mineral deposit capacity of non-
tumoral human osteoblasts in culture [31].
A previous study by Giuliani et al. [28] showed that
bisphosphonates inhibited the production of IL-6 in-
duced by IL-1b and TNF-a in MG-63 osteoblast-like
cells obtained from a human osteosarcoma. The dis-
Fig. 5. Northern blot analysis of IL-6 and IL-11 after treat-
ment of human osteoblasts with alendronate or etidronate.
Cultures were treated with TNF-a + IL-1b in the presence of
FCS. Three concentrations of (A) alendronate (10)7, 10)9,
10)12 M) or (B) etidronate (10)4, 10)6, 10)9 M) were tested.
Total RNA was isolated and subjected to Northern blot
analysis. Neither alendronate nor etidronate aﬀected IL-6 or
IL-11 mRNA levels. Cyclophilin A mRNA expression was
determined as the internal control. (Mean ± SEM of three
independent experiments. P < 0.05 Scheﬀe’s f-test)
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crepancy between these results and those of our study
are probably derived from diﬀerences in the experi-
mental models used. First of all, every experiment in the
present study was performed on homogeneous lines of
non-neoplastic human osteoblasts obtained from pri-
mary cultures of cells showing a mature osteoblast
phenotype. This system is much more representative of
normal physiology than osteogenic sarcoma cell lines, in
which cytokine production might be altered by trans-
formation-related changes [30]. On the other hand, Gi-
uliani et al. assessed the eﬀects of bisphosphonates on
IL-6 secretion by means of a bioassay. It is well known
that this is an indirect method, as it does not quantify
the secreted protein but rather measures its activity.
Instead of this, the present study was performed using
sensitive quantitative ELISA techniques, permitting
concentrations of speciﬁc cytokines in the conditioned
medium to be quantiﬁed. Moreover, results of ELISAs
concurred with those of Northern blot analysis of IL-6
mRNA levels.
In contrast, Sanders et al. [29] studied the eﬀect of
alendronate on IL-6 production by two diﬀerent models:
UMR-106 rat osteoblastic osteosarcoma cells and fetal
rat limb bone culture. The results of their study con-
tradicted those of Giuliani et al. Thus, Sanders et al.
obtained an increase in IL-6 secretion when treating the
cultures with alendronate. However, this was only ob-
served under intensive stimulation with IL-1b. Interest-
ingly, in the fetal rat limb bone culture model,
dissociation was observed between the eﬀect of alendr-
onate on resorption and that on IL-6 levels. Again, it is
conceivable that the diﬀerences between our results and
those of Sanders et al. are due to diﬀerences in culture
models and in the methods used for quantiﬁcation. Once
more, the model used in the present study is more rep-
resentative of normal physiology than those using rat
osteosarcoma cell lines or fetal and neonatal rat cells. It
is well known that transformed and fetal cells have very
diﬀerent biological behavior compared with human
non-neoplastic adult cells. Furthermore, in bone organ
culture, cytokine production by marrow cells other than
osteoblasts may be a confounding factor. Finally,
Sanders et al., like Giuliani et al., used a bioassay as a
quantiﬁcation method, with the limitations we men-
tioned before.
Although it has been shown that IL-6 and IL-11 are
interleukins that play an important role in the activation
of bone resorption [23, 32], the results of our study allow
us to conclude that alendronate and etidronate do not
operate indirectly on resorption by modifying these cy-
tokine levels. In any event, it is not possible to rule out
the possibility that an eﬀect of bisphosphonates on os-
teoblast-mediated resorption could occur. In this way,
knowledge of osteoclast activity inhibitors [33–35] has
led some authors to suggest that indirect action of bis-
phosphonates on resorption would not be exerted
through the inhibition of resorption-stimulating osteo-
blastic factor secretion, but rather by stimulating the
secretion of resorption-inhibiting factors. In this regard,
Nishikawa et al. [36] and Vitte´ et al. [13] demonstrated
that bisphosphonates stimulate secretion of osteoclast-
inhibiting molecules by osteoblasts.
In conclusion, the present study shows that human
non-neoplastic osteoblasts have no native synthesis of
IL-11 in vitro. In addition, this study also demonstrates
that alendronate and etidronate do not regulate the
synthesis of IL-6 and IL-11 in these cells. Therefore, a
possible indirect, osteoblast-mediated action of bis-
phosphonates on bone resorption would not be exerted
through reduction in osteoblastic synthesis of IL-6 and
IL-11.
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